Triple-negative breast cancer (TNBC), one of multiple clinical subtypes of breast cancer (BC) defined by a lack of expression of estrogen receptors (ER), progesterone receptors (PR), and the HER-2/neu epidermal growth factor receptors [1], accounts for 10-15% of all BC cases [2]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.